Abstract

MEJIA-BURITICA, Leonardo; TORRES-HERNANDEZ, José Domingo  and  VASQUEZ, Gonzalo de Jesús. Acute promyelocytic leukemia. State of the art. Iatreia [online]. 2021, vol.34, n.1, pp.42-53. ISSN 0121-0793.  https://doi.org/10.17533/udea.iatreia.76.

Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML) that results from a balanced translocation between chromosomes 15 and 17, which involves the gene encoding the retinoic acid receptor alpha (RARA) on chromosome 17 and the gene for promyelocytic leukemia (PML) on chromosome 15, causing the translocation t (15; 17) PML / RARA. This rearrangement originates the PML / RAR alpha fusion protein, which blocks the differentiation of myeloid stem cells at the promyelocyte stage. APL affects young adults more frequently and carries a high risk of early mortality, especially due to development of severe coagulopathy that, without treatment, is invariably fatal. Early diagnosis, supportive treatment, and the introduction of drugs that promote the terminal differentiation of pathological promyelocytes such as alltrans retinoic acid (ATRA) and arsenic trioxide (ATO), have currently made this a curable disease with high rates of complete remission.

Keywords : Arsenic Trioxide; Leukemia, Promyelocytic, Acute; Tretinoin.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )